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ABSTRACT 
Objective: To establish the method of isolation and culture of 
human glioblastoma neurospheres, and the purification of their 
stem cells, followed by the process of obtaining tumor subspheres, 
immunophenotypically characterizing this clonogenic set. Methods: 
Through the processing of glioblastoma samples (n=3), the following 
strategy of action was adopted: (i) establish primary culture of 
glioblastoma; (ii) isolation and culture of tumor neurospheres; (iii) 
purify cells that initiate tumors (CD133+) by magnetic separation 
system (MACS); (iv) obtain tumor subspheres; (v) study the 
expression of the markers nestin, CD133, and GFAP. Results: The 
study successfully described the process of isolation and culture of 
glioblastoma subspheres, which consist of a number of clonogenic 
cells immunophenotypically characterized as neural, which are 
able to initiate tumor formation. Conclusion: These findings may 
contribute to a better understanding of the process of gliomagenesis.
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RESUMO 
Objetivo: Estabelecer o método de isolamento e cultivo das 
neuroesferas de glioblastoma humano, bem como purificação de 
suas células-tronco, seguido do processo de obtenção de subesferas 
tumorais, caracterizando imunofenotipicamente esse conjunto 
clonogênico. Métodos: Por meio do processamento de amostras de 
glioblastomas (n=3), cumpriu-se a seguinte estratégia de ação: (i) 
estabelecimento da cultura primária de glioblastoma; (ii) isolamento 
e cultura de neuroesferas tumorais; (iii) purificação das células que 
iniciam os tumores (CD133+) por sistema de separação magnética 
(MACS); (iv) obtenção subesferas tumorais; (v) estudo da expressão 
de marcadores GFAP, CD133 e nestina. Resultados: Este estudo 
descreveu com sucesso o processo de isolamento e cultivo de 
subesferas de glioblastoma, as quais são constituídas por um conjunto 
clonogênico de células caracterizadas imunofenotipicamente como 
neurais, capazes de iniciar a formação tumoral. Conclusão: Estes 
achados poderão contribuir para a compreensão do processo de 
gliomagênese.
Descritores: Glioblastoma; Cultura celular; Células-tronco neoplásicas; 
Antígenos
INTRODUCTION
According to the World Health Organization (WHO)(1), 
central nervous system (CNS) tumors are classified 
into seven major groups which include primary tumors 
(neuroepithelial, meninges, paraspinal and cranial 
nerves, germ cell, sellar region, and hematopoietic) and 
secondary tumors or metastatic.
Gliomas are tumors that arise from glial cells 
and include astrocytomas, oligodendrogliomas, 
oligoastrocitomas (also called mixed gliomas), and 
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ependymomas. Gliomas are part of the group of 
neuroepithelial tumors and account for 31% of primary 
tumors and 80% of malignant tumors of the CNS. The 
astrocytoma group corresponds to 76% of the gliomas, 
and glioblastoma represents 53.7%(2). Glioblastoma is 
the most frequent and malignant of the astrocytomas, 
and despite numerous advances in the diagnosis and 
treatment of these tumors, the prognosis remains very 
limited(3,4). 
Glioma is also described as the most common 
human CNS neoplasm,(2) and it is very difficult to 
treat due to several factors: (i) it is infiltrative; (ii) it 
is composed of cells with different morphological and 
functional characteristics expressing various neuronal 
markers; (iii) it is highly resistant to radiation and 
chemotherapy processes(5). These characteristics are 
probably due to the competence of tumor cells which 
is similar to the competence of stem cells, explaining 
high rate of recurrence of the disease or its primary 
resistance to treatment. Therefore, it is extremely 
important to search for new approaches referring 
to the genesis, progression and clinical behavior of 
brain tumors. 
Among the theories that seek to determine the 
molecular genesis of CNS tumors, one that is gaining 
many supporters in recent years is the hypothesis of 
tumor stem cells(6,7). Recent studies have shown that the 
onset and progression of some malignant tumors can 
be determined by a subpopulation of tumorigenic cells 
with great capacity of self-renewal, called tumor stem 
cells(5,8).
The first prospect of identification and 
characterization of tumor stem cells of different 
phenotypes was reported in human brain tumors with 
increased expression of the CD133 antigen(5).
Monoclonal anti-CD133 antibodies have been 
previously used to identify normal human neural stem 
cells(9). The brain tumor stem cell has been isolated 
exclusively by the expression of this antigen (CD133). 
Three evidence suggested that these CD133+ cells were 
brain tumor stem cells: (1) they originated clonogenic 
cell sets (neurospheres); (2) they underwent the process 
of self-renewal and proliferation; and (3) they 
differentiated and returned to express the phenotype 
of the tumor that originated them when implanted in 
immunodeficient animals. 
A study conducted by Uchida et al.(10) described 
that purified CD133+ cells generated neurospheres in 
culture, and differentiated into neurons and glial cells 
that were capable of cell differentiation. Other groups 
have also verified that, contrary to CD133- cells, 
CD133+ cells were capable of inducing brain tumors in 
in vivo models(11,12). Therefore, these studies strongly 
suggest that the subpopulation of cells that initiate 
brain tumors are concentrated in a small fraction of 
CD133+ cells.
OBJECTIVE
This study aimed at establishing the method of isolation 
and culture of human glioblastoma neurospheres, and 
the purification of their stem cells, followed by the process 
of obtaining tumor subspheres, immunophenotypically 
characterizing this clonogenic set.
These objectives adopted the following action 
strategy: (i) establishment of primary cultures of 
glioblastoma; (ii) isolation and culture of tumor 
neurospheres; (iii) purification of cells that initiate 
tumors by selection with CD133 magnetic microbeads; 
(iv) flow cytometry of the CD133+ tumor cells; 
(v) obtaining tumor subspheres; (vi) study of the 
expression of GFAP (acidic fibrillary glial and 
intermediate filament protein specific for astrocytes 
in the NS), CD133 (cell membrane glycoprotein 
highly expressed in glial and neuronal stem cells) 
and nestin (intermediate filament protein class found 
in the embryonic development phase of the human 
brain) markers.
METHODS
This study involved the processing of samples of 
glioblastoma (n=3) obtained in surgical procedures 
of the Neuro-Oncology Center of the Hospital Israelita 
Albert Einstein (HIAE). The samples were donated by 
patients who signed the free and informed consent 
form (CEP 687).
The diagnosis of this tumor was based on the 
findings of magnetic resonance images previously 
discussed by the Integrated Neuro-Oncology Program 
and the Laboratory of Pathology of HIAE. 
As control for the study, immunohistochemistry 
reactions for GFAP, a biomarker used in the diagnosis 
of glioblastoma(13) were conducted.
The study followed the strategy of action described 
below.
Establishment of primary culture of samples of glioblastoma
The fresh tumor samples of glioblastoma were washed, 
fractionated in PBS (1X), and enzymatically dissociated 
with 0.3% collagenase. The cells were resuspended in 
DMEM-LG medium: Dulbecco’s Modified Eagle’s 
Medium-low glucose supplemented with 10% Fetal 
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Bovine Serum and 1% Antibiotic-Antimycotic (100X) 
and L-Glutamine 200mm (100x), and plated at a 
density of 5x106 cells (alive) per 25cm2, which were 
cultivated in an incubator (Thermo Fisher Scientific 
Inc. 3110, Waltham, MA) equipped with 5% CO2 
at 37°C for at least 24 hours. After reaching 80% 
confluency, glioblastoma cells were analyzed by 
immunocytochemical assays using CD133 antibody 
(1:100 Abcam, Cambridge, MA), as indicated by the 
manufacturer (DAKO, Biogen).
Culture of tumor neurospheres
The cells obtained from the primary culture of tumor 
cells were resuspended in a culture medium, defined as 
a medium for growing brain tumor stem cells (CTTC), 
composed of Dulbecco’s Modified Eagle’s Medium/
F12 (Gibco®), supplemented with N2 (Gibco®), EGF 
(20ng/mL; Invitrogen), bFGF (20ng/mL; Gibco®), 
leukemia inhibitory factor (LIF, Chemicon), and B27 
(1:50; Life Technologies Corporation), and plated at a 
density of 2x104 viable cells in 24-well plates. The cells 
were cultivated in an incubator (3110 Thermo Fisher 
Scientific Inc., Waltham, MA) equipped with 5% CO2 
at 37°C, and the culture medium was changed every 3 
days(14).
Purification of cells that initiate tumors by magnetic 
separation using the marker CD133 antigen 
The colonies of tumor neurospheres were dissociated 
using StemPro® Accutase® (Invitrogen) Cell Dissociation 
Reagent. For magnetic marking we used CD133 
(MACS®, Miltenyi Biotech) magnetic microbeads. The 
cells were labeled with CD133/2-PE (Miltenyi Biotech 
clone AC133), and the separation efficiency of the 
positive cell fractions was evaluated by FACSARIA 
(BD Biosciences, San Jose, CA) flow cytometry, and 
analyzed using the FACSDIVA (BD Biosciences, San 
Jose, CA) software. This study allowed the separation 
of CD133+ cell fractions and CD133- cell fractions,(13) 
and the CD133+ fraction was analyzed by transmission 
electron microscopy, following a routine protocol(15).
Formation of tumor subspheres
The CD133+ cells and the CD133- cells isolated by 
magnetic separation were suspended in a culture 
medium called “medium for brain tumor stem cells” 
and plated at a density of 2x104 live cells in 96-well 
plates. This method allowed the formation of tumor 
subspheres composed exclusively of subpopulations of 
purified CD133+ cells.
Immunophenotypic characterization of tumor subspheres
For immunophenotypic characterization of tumor 
subspheres, digital multiparameter flow cytometry 
was used (FACSARIA, Becton Dickinson, San Jose, 
CA) and the experiments were performed using 
commercially available monoclonal antibodies: GFAP 
(clone:51-10C9, BD Pharmingen, San Diego, CA), 
nestin (clone:AD2; BD Pharmingen, San Diego, CA) 
and CD133 APC (clone:/2293-C3; Miltenyi Biotec, 
Bergisch Gladbach, Germany), sheep anti-mouse 
secondary antibody (PE; Chemicon, Temecula, CA), 
and isotype-specific monoclonal antibodies. Staining, 
acquisition and analysis techniques were performed 
according to the manufacturer’s instructions. 
RESULTS
The morphological and histological analysis indicated 
the presence of a highly infiltrative brain tumor tissue, 
with a gradual increase in cellularity (Figure 1A). 
The neoplastic cells were predominantly spindle-
shaped cells and derived from mature astrocytes (Fig. 
1A). The capillary endothelial cells were numerous 
and swollen (Figure 1A), an effect related to the 
high vascular proliferation. The presence of GFAP 
defined the glial lineage of the tumor (Figure 1B). 
The immunohistochemical analyses (Figure 1B) were 
strongly positive for GFAP, and the cells were neoplastic, 
immature-appearing, elongated, and spindle-shaped.
Glioblastoma tissue samples were used for 
establishing the primary culture of those tumors, 
which was homogeneous with spindle-shaped cells 
arranged in multidirectional bundles (Figure 1D). 
Immunocytochemical tests revealed the expression of the 
antigenic marker CD133 in the tumor neurospheres of 
the glioblastoma primary culture (Figures 1D and F). 
The cells obtained from the primary culture of 
these tumors were resuspended in culture medium 
CTTC, in which the isolation and culture processes of 
the glioblastoma-derived neurospheres were conducted 
(Figures 1G and H).
Immunophenotypic characterization was then 
conducted by flow cytometry tests, evaluating the 
efficiency of magnetic separation of cell fractions 
positive for the antigenic marker CD133 in samples 
of tumor neurospheres (89% of CD133+ cells), 
standardizing the sorting process for CD133+ cells 
(Figure 2A). Only these CD133+ cells were capable, 
in culture, of generating glioblastoma subspheres 
(Figure 2B, Figures 3A to 3E) which did not happen in 
compared fractions of CD133- cells (Figure 3F).
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Figure 3. Culture of glioblastoma tumor subspheres obtained after the selection 
process of CD133+ cells by MACS. (A and B) Magnification: 200X. (C and F) 
Magnification: 400X. (D) Magnification: 600X. (E) Analysis of the transmission 
electron microscopy images of the tumor subspheres; arrow: electron-dense 
points showing the magnetic microbeads conjugated to anti-CD133; bar: 1µm. 
(F) Negative control for the forming process of tumor subspheres obtained from 
CD133- cells
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Figure 1. Histological and immunohistochemical tests on samples of 
glioblastoma obtained in histotechnical paraffin sections. (A) Hematoxylin 
and Eosin (H/E). (B) GFAP. (C) Negative control PH+ (GFAP). (A, B and 
C) Magnification: 200X. (D) Primary culture of glioblastoma. (E and F) 
Immunocytochemistry test for CD133 in primary culture (arrow: expression of the 
antigenic marker CD133). (G and H) Isolation and growth of glioblastoma tumor 
neurospheres. (D, E, G and H) Magnification: 400X. (F) Magnification: 600X
A B
Figure 2. (A) Immunophenotypic characterization by flow cytometry tests, evaluating the efficiency of magnetic separation of cell fractions positive for the antigenic 
marker CD133 in tumor neurosphere samples (89% of CD133+ cells). (B) Culture of glioblastoma tumor subspheres obtained after the selection process of CD133+ cells, 
compared with the absence of subspheres obtained from CD133- fractions (negative control). (B) Magnification: 400X
The glioblastoma-derived subspheres were described as 
cell aggregates or a set of clonogenic cells (Figure 3), 
which were immunophenotypically characterized showing 
the pattern of expression of the markers GFAP (87%) 
and nestin (39%) (Figure 4). 
Figure 3E, as evidenced by ultrastructural analysis 
of transmission electron microscopy, described the 
presence of electron-dense lumps on the glioblastoma 
subspheres, pointing to the magnetic beads conjugated 
to anti-CD133 antibodies.
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DISCUSSION
Despite recent advances in the treatment of human 
brain cancer, the cellular and molecular mechanisms 
by which gliomas begin and are established have not 
been elucidated. Recent studies have shown that the 
onset and progression of some malignant tumors can 
be determined by a subpopulation of tumorigenic cells 
with great capacity of self-renewal, called tumor stem 
cells(16,17).
The tumor stem cell hypothesis describes that brain 
tumors, despite being a heterogeneous mass of cells, are 
composed of a rare cell population (CD133+), which is 
capable of initiating the formation of a new tumor or 
metastasis, and its nature is defined by the formation of 
neurospheres(6). 
The investigation process of brain tumor stem cells 
remains inconclusive, and their function still cannot 
be objectively established. To fully understand the 
biology of brain tumor stem cells, it is highly desirable 
to establish permanent lines of research in the isolation, 
culture and purification processes of their stem cells. 
Therefore, this study aimed to establish the method 
of isolation and culture of tumor stem cells, properly 
classified as glioblastoma. The study was based initially 
in the primary culture process of the tumor, described as 
a homogeneous mass of spindle-shaped cells arranged in 
multidirectional bundles. Immunocytochemical assays, 
performed in these primary cultures of glioblastoma, 
revealed the expression of the antigenic marker CD133 
in the initial cell aggregates during the formation of 
possible neurospheres, noting that the isolation and 
culture processes of glioblastoma tumor neurospheres 
occurred only after the use of a culture medium suitably 
supplemented (medium CTTC).
The purification process of the cells that initiate 
tumors, performed by a magnetic selection method 
using MACS, attributed to CD133+ cells the ability to 
generate, in culture, glioblastoma tumor subspheres.
These glioblastoma tumor subspheres were 
described as cell aggregates or a set of clonogenic cells 
immunophenotypically characterized by the expression 
of markers such as GFAP, indicating the glial origin of 
the tumor cells, and nestin, an intermediate filament 
characteristic of immature cells, present in high levels 
in stem cells derived from cell lines of the central 
nervous system(8).
Obviously, these tumor subspheres also expressed 
the antigenic marker CD133, present in neural tumor 
stem cells, whose ultrastructural description revealed 
the presence of magnetic beads coupled to anti-CD133 
antibodies on the glioblastoma tumor subspheres. 
In its initial results, this study showed that the isolation 
and culture processes of glioblastoma subspheres actually 
give immunophenotypic characteristics of neural stem 
cells to the tumor cells that constitute them.
The results described in this study are based on 
recent findings in literature, which characterized the 
immunophenotypic profile of glioblastoma stem cells, 
Figure 4. Immunophenotypic characterization by flow cytometry tests showing the pattern of expression of markers GFAP and nestin in glioblastoma tumor subsphere 
samples
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describing a set of cell markers (CD133, nestin, and 
GFAP) with tumorigenic properties(18,19).
Parallel studies defined another set of antigenic 
markers in the characterization process of brain tumor 
stem cells, such as CXCR4, Sox2, Musachi-1, and 
Nanog(20).
This study used the molecular marker CD133 as a 
predictor in the substantiation of the selection process 
of stem cells. This approach follows previous patterns 
found in literature, which identified a molecular 
signature for the CD133+ glioblastoma cells, similar 
to human embryonic stem cells(21). These authors 
determined that these CD133+ cells were glioblastoma 
stem cells, and also identified a more aggressive subtype 
of the disease(21), insofar as these cells are highly resistant 
to radiation and chemotherapy procedures(16).
Other studies have also suggested that the expression 
of the marker CD133+ could be a molecular indicator 
of glioblastoma spreading(16,22), which justifies its 
prognostic value(23) and the recent demand for drugs 
that act against this subset of cells (CD133+) in order 
to inhibit or retard the proliferation of highly invasive 
gliomas(24).
CONCLUSION
This study proposes a process of isolation, 
characterization and culture of glioblastoma stem 
cells, which can contribute to the study of the genesis 
of brain tumors, identifying the cell responsible for the 
origin and spreading of tumors, and thus elucidating 
new therapeutic paradigms for neuro-oncology.
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